Project B02: Technical cooperation for early screening of chronic diseases of the nervous system

Project name: Nervous system chronic disease early screening technical cooperation project

Company profile

A Biotechnology Co., Ltd. in Zhejiang is a high-tech enterprise integrating research and development, production, sales and service, focusing on the early screening of nervous system diseases, auxiliary diagnosis and the development of intervention and rehabilitation products. The company is committed to promoting the early detection and effective intervention of neurological chronic diseases, and providing better health management solutions for patients.

Cooperation Demand

1. Research and Technology direction:

• Early screening technology for chronic diseases: Develop and optimize early screening technology for chronic diseases of the nervous system, aiming to improve the accuracy of screening and the effectiveness of early intervention.

• Development of auxiliary diagnostic tools: Combined with advanced biomedical technology, research and development of auxiliary diagnostic tools to improve the diagnostic accuracy of neurological diseases.

• Intervention and Rehabilitation technologies: Explore and develop effective intervention and rehabilitation technologies for neurological disorders to promote healthy recovery of patients.

2. Expert areas of expertise and cooperation requirements:

• neurosciences

• biomedical engineering

• neuropathology

• medical device development

Experts with rich research experience in the above fields can provide technical guidance for the early screening of chronic diseases and the research and development of related products, and participate in the development and optimization of key technologies.

Cooperative Target

The biotechnology Co., Ltd. hopes to enhance the company's research and development capabilities in the screening and intervention technology of nervous system chronic diseases through cooperation with experts, and promote the innovation and market application of early screening products for nervous system diseases.